Back to Trials
NCT07314346PHASE1RecruitingAccepts Healthy Volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Atea Pharmaceuticals, Inc.

Start Date

1/7/2025

Completion Date

8/1/2026

Summary

Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug. * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2. * Willing to comply with the study requirements and to provide written informed consent. Exclusion Criteria: * Infected with hepatitis B virus, hepatitis C virus, HIV. * Abuse of alcohol or drugs. * Use of other investigational drugs within 28 days prior to Day -5. * Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine/naloxone as assigned maintenance therapy). * Other clinically significant medical conditions or laboratory abnormalities.

Interventions

DRUG

Buprenorphine/Naloxone + BEM/RZR

DRUG

Methadone +BEM/RZR

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy Volunteer Study

Locations

Atea Study Site

Hollywood, Florida 33019

United States

Atea Study Site

Overland Park, Kansas 66212

United States

Atea Study Site

Marlton, New Jersey 08053

United States